Skip to main content
SpringerLink
Log in

Upadacitinib: safety profile in rheumatoid arthritis

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. SELECT-EARLY; SELECT-NEXT; SELECT-COMPARE; SELECT-MONOTHERAPY; and SELECT-BEYOND.

Reference

  • Cohen SB, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Annals of the Rheumatic Diseases : 28 Oct 2020. Available from: URL: http://dx.doi.org/10.1136/annrheumdis-2020-218510

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Upadacitinib: safety profile in rheumatoid arthritis. Reactions Weekly 1830, 11 (2020). https://doi.org/10.1007/s40278-020-85961-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-85961-8

Search

Navigation